Schlumberger M, Baudin E, Travagli J P
Presse Med. 1998 Oct 3;27(29):1479-81.
MANAGEMENT STRATEGIES: Management of papillary and follicular cancer of the thyroid varies somewhat between centers because of the generally good prognosis and the absence of well-controlled therapeutic trials. The internationally recognized TNM system is widely used to modulate treatment and follow-up to the individual situation.
Surgery is indicated in well-differentiated thyroid cancer. Total thyroidectomy is required for clinically patent tumors (> or = 1 cm) and small tumors (< 1 cm) recognized prior to surgery. For small tumors found at histology examination, reoperation is discussed in terms of prognosis. Post-operative 131-iodine is indicated when surgical resection is incomplete or in case of unfavorable prognosis. External radiotherapy is currently reserved for exceptional cases with unremoved tumoral tissue unresponsive to 131-iodine.
FOLLOW-UP: All operated patients are given L-thyroxine to achieve euthyroidism and low TSH levels (< 0.1 microU/ml). Early detection of relapse is based on combined thyroglobulin assay and whole body 131-iodine scintigraphy. Both are performed during the first year of follow-up after a period of thyroid hormone withdrawal. Human recombinant TSH will soon be available allowing selection of patients with a detectable thyroglobulin level after stimulation; these patients should have a 131-iodine scintigram. If thyroglobulin remains undetectable during L-thyroxine treatment, an annual dosage is indicated and other exams are unwarranted.
Surgery is indicated in case of small areas of active recurrent tumoral tissue in a cervical location. If a high-sensitivity scintigram does not show iodine uptake, the surgical procedure is completed by radiotherapy or possibly chemotherapy with doxorubicin. Small recurrent tumors in other areas respond to 131-iodine (3.7 GBq). Surgery, 131-iodine and radiotherapy are usually indicated for large ectopic recurrences. Chemotherapy is ineffective.
Standard primary therapy generally provides cure and most patients are followed by annual thyroglobulin and TSH assays. Other explorations beginning with a whole-body 131-scintigram may be indicated in selected patients.
管理策略:由于甲状腺乳头状癌和滤泡状癌的总体预后良好且缺乏严格对照的治疗试验,各中心在其管理策略上存在一定差异。国际认可的TNM系统被广泛用于根据个体情况调整治疗和随访方案。
分化型甲状腺癌需进行手术治疗。对于临床可触及的肿瘤(≥1厘米)以及术前发现的小肿瘤(<1厘米),需要进行全甲状腺切除术。对于组织学检查发现的小肿瘤,需根据预后情况讨论是否再次手术。手术切除不完全或预后不佳时,术后需进行131碘治疗。目前,外照射放疗仅用于无法切除且对131碘无反应的肿瘤组织的特殊病例。
所有接受手术的患者均需服用左甲状腺素以维持甲状腺功能正常并使促甲状腺激素水平降低(<0.1微单位/毫升)。复发的早期检测基于甲状腺球蛋白检测和全身131碘闪烁扫描。这两项检查均在甲状腺激素停药后的随访第一年进行。人重组促甲状腺激素即将可用,可用于选择刺激后甲状腺球蛋白水平可检测的患者;这些患者应进行131碘闪烁扫描。如果在左甲状腺素治疗期间甲状腺球蛋白仍无法检测到,则每年进行一次剂量检测,无需进行其他检查。
颈部出现小面积活跃复发肿瘤组织时需进行手术。如果高灵敏度闪烁扫描未显示碘摄取,则手术可辅以放疗或可能的阿霉素化疗。其他部位的小复发肿瘤对131碘(3.7吉贝可)有反应。对于大的异位复发,通常需要手术、131碘和放疗。化疗无效。
标准的初始治疗通常可治愈疾病,大多数患者每年进行甲状腺球蛋白和促甲状腺激素检测。对于部分患者,可能需要从全身131碘闪烁扫描开始进行其他检查。